TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9522686

Group type: EXPERIMENTAL
Intervention: Prepared dentin surfaces were cleaned with Tubulicid Red Label and covered with Tubulitec Primer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All-Bond 2 Primer was applied to the prepared dentin surface
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group: prepared surfaces were left unprotected after preparation
Number of subjects: 12
Study: 2060527

Group type: EXPERIMENTAL
Intervention: Pyrimethamine (50 mg/day) plus Clindamycin (2.4 g/day)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Pyrimethamine (50 mg/day) and Sulfadiazine (4.0 g/day)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 281
Study: 6416698

Group type: EXPERIMENTAL
Intervention: thio-TEPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VM-26
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: epodyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oral pyridoxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: doxorubicin (Adriamycin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 0
Study: 31755526

Group type: EXPERIMENTAL
Intervention: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV) on an accelerated dosing schedule (months 0, 2, and 6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV) given concurrently with Japanese encephalitis (JE) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV)
Number of subjects: 0
Study: 31412035

Group type: EXPERIMENTAL
Intervention: Active screening intervention conducted in 28 villages
Number of subjects: 10963

Group type: COMPARATOR
Intervention: Passive screening (historically used)
Number of subjects: 10963
Study: 28576207

Group type: EXPERIMENTAL
Intervention: Air tamponade
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SF6 tamponade
Number of subjects: 32
Study: 26458331

Group type: EXPERIMENTAL
Intervention: Values inventory intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 120
Study: 24438321

Group type: EXPERIMENTAL
Intervention: Active sTMS with fixed frequency at the subject's alpha frequency
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Active sTMS with random stimulus frequency (8 Hz to 13 Hz)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham sTMS
Number of subjects: 52
Study: 22284441

Group type: EXPERIMENTAL
Intervention: Longitudinal GFR estimates from creatinine‐based equations
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Baseline eGFR > 40 mL/min/1.73 m2 and urine protein‐creatinine ratio < 0.22 g/g
Number of subjects: 846
Study: 18853090

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17270007

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 29
Study: 15126520

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.0125 mg/kg.d, increased to 0.025 mg/kg.d as tolerated, or decreased to 0.00625 mg/kg.d for 12 months
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 166
Study: 11394590

Group type: EXPERIMENTAL
Intervention: Individual SPM training (n = 16)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Group SPM training (n = 16)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 41
Study: 9543436

Group type: EXPERIMENTAL
Intervention: lamivudine (3TC)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: 3TC plus loviride
Number of subjects: 1840

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: 3TC
Number of subjects: 1840
Study: 8036820

Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis A vaccine (0.1 ml each, three doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intramuscular hepatitis A vaccine (control group)
Number of subjects: 43
Study: 2659740

Group type: EXPERIMENTAL
Intervention: recombinant interferon‐alpha‐2C (rIFN‐alpha‐2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: VMCP chemotherapy alone
Number of subjects: 33
Study: 31397611

Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + Er,Cr:YSGG LAI
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Saline + Er,Cr:YSGG LAI
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + PUI
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Saline + PUI
Number of subjects: 72

Group type: COMPARATOR
Intervention: Positive control (no treatment)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Negative control (no bacteria)
Number of subjects: 72
Study: 30273508

Group type: EXPERIMENTAL
Intervention: Access to online resources, group and private forums, and videoconferencing with a therapist.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 28
Study: 28578208

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioural Therapy (ICBT)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 547
Study: 26050967

Group type: EXPERIMENTAL
Intervention: V0162 (1600 μg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23456567

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 30986

Group type: EXPERIMENTAL
Intervention: Non-aspirin antiplatelets
Number of subjects: 30986

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator therapy (IV-tPA)
Number of subjects: 30986

Group type: EXPERIMENTAL
Intervention: Stent use
Number of subjects: 30986
Study: 21480976

Group type: EXPERIMENTAL
Intervention: Topical phenytoin dressing
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control dressing
Number of subjects: 65
Study: 18049795

Group type: EXPERIMENTAL
Intervention: Tirofiban 0.4 microg/kg/min over 30 min plus 0.15 microg/kg/min over 24 h (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg plus tirofiban (Group C)
Number of subjects: 60
Study: 16736077

Group type: EXPERIMENTAL
Intervention: Tailored message booklet with brief advice
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Brief advice conditions (tailored or generic)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Younger adult women (ages 19-22) who received brief advice
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Generic message booklet with brief advice
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Generic message booklet only
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Tailored message booklet only
Number of subjects: 575
Study: 12755777

Group type: EXPERIMENTAL
Intervention: Immediately loaded FRIALIT-2(R) implants
Number of subjects: 7

Group type: COMPARATOR
Intervention: Non-loaded implants
Number of subjects: 7
Study: 10983904

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (walking, jogging, cycling at 50-60% HRR for 30-45 minutes, progressing to 80-85% HRR for 45-60 minutes, 3-4 times per week for 9 months)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 17
Study: 8797143

Group type: EXPERIMENTAL
Intervention: Irbesartan 10 mg and above
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Irbesartan (various doses: 1, 5, 10, 25, 50, and 100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1480537

Group type: EXPERIMENTAL
Intervention: 2 mg trandolapril
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6737952

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29696916

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (at Fengchi, Ganshu, Shenshu, Quchi, Zusanli, Sanyinjiao, Taichong), once every two weeks for 3 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: Lotensin (10 mg, once a day)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Observation group
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 27170340

Group type: EXPERIMENTAL
Intervention: Basiliximab (IL2Ra) 20 mg on Day 0 and Day 4
Number of subjects: 213

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (rATG) 1.0 mg/kg/day from Day 0 to Day 4
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Basiliximab (IL2Ra)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (rATG)
Number of subjects: 213
Study: 26202784

Group type: EXPERIMENTAL
Intervention: Defatted cows' milk
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Partially defatted cows' milk
Number of subjects: 13

Group type: COMPARATOR
Intervention: Whole cows' milk
Number of subjects: 13
Study: 24124716

Group type: EXPERIMENTAL
Intervention: Furosemide 5-40 mg injection in standard group (CVP < 8 mm Hg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (CVP not < 8 mm Hg)
Number of subjects: 56
Study: 20807459

Group type: EXPERIMENTAL
Intervention: Whole pea flour (WPF)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fractionated pea flour (FPF)
Number of subjects: 23

Group type: COMPARATOR
Intervention: White wheat flour (WF)
Number of subjects: 23
Study: 18194332

Group type: EXPERIMENTAL
Intervention: Mouthwash and oral gel containing lactoperoxidase, lactoferrin, and lysozyme
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16600923

Group type: EXPERIMENTAL
Intervention: Dairy products enriched with cis-9,trans-11 CLA (1.421 g/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control dairy products (0.151 g/d CLA)
Number of subjects: 32
Study: 14748110

Group type: EXPERIMENTAL
Intervention: Burst TENS stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: No stimulus (control)
Number of subjects: 18
Study: 10966004

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thienopyridines (ticlopidine and clopidogrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study: 9348572

Group type: EXPERIMENTAL
Intervention: Pelvic radiation therapy plus fluorouracil (5-FU)-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative bolus 5-FU/leucovorin combined-modality therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tegafur and uracil (UFT) with oral leucovorin plus pre- or postoperative radiation therapy
Number of subjects: 0
Study: 8446442

Group type: EXPERIMENTAL
Intervention: Lidocaine (10‐16 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3743684

Group type: EXPERIMENTAL
Intervention: Noradrenaline (0.25 micrograms X kg‐1 X min‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 31669496

Group type: EXPERIMENTAL
Intervention: TTM-based dietary education program for six months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study: 30266774

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 0
Study: 26542419

Group type: EXPERIMENTAL
Intervention: Moderate-intensity stationary cycling programme for 16 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group with no exercise intervention
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Greater compliance with exercise protocol
Number of subjects: 75
Study: 24531785

Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23161117

Group type: EXPERIMENTAL
Intervention: Radiotherapy (70‐70.2 Gy in 35‐39 fractions)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Radiotherapy (37.8‐55.8 Gy in 21‐31 fractions) followed by total laryngectomy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Radiotherapy (with or without chemotherapy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 19
Study: 21397987

Group type: EXPERIMENTAL
Intervention: Double J ureteral catheter
Number of subjects: 194

Group type: COMPARATOR
Intervention: Catheter-free
Number of subjects: 194
Study: 19080093

Group type: EXPERIMENTAL
Intervention: Alprostadil (10 ng/ml added into the prime solution and continuous pump infusion of 10 ng/kg/min via central vein until the end of operation)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ulinastatin (20,000 U/kg divided into several doses added into the prime solution)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combination of Alprostadil and Ulinastatin (according to the above protocols)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 58
Study: 16493178

Group type: EXPERIMENTAL
Intervention: Contraindication label
Number of subjects: 466
Study: 14570791

Group type: EXPERIMENTAL
Intervention: Bupivacaine 8 mg + sufentanil 2.5 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 8 mg + sufentanil 2.5 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ropivacaine 12 mg + sufentanil 2.5 microg
Number of subjects: 90
Study: 11116071

Group type: EXPERIMENTAL
Intervention: Higher plasma lycopene levels (above median concentration)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Lower plasma lycopene levels (below median concentration)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Low plasma lycopene levels
Number of subjects: 520
Study: 8667097

Group type: EXPERIMENTAL
Intervention: Postdischarge clinic (once a week)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Usual discharge practices
Number of subjects: 751
Study: 1403459

Group type: EXPERIMENTAL
Intervention: Oral gentamicin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 3801332

Group type: EXPERIMENTAL
Intervention: Pre-harvest retted flax dust
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dew retted flax dust
Number of subjects: 11
Study: 29275332

Group type: EXPERIMENTAL
Intervention: Bimekizumab (240 mg/160 mg/160 mg; 80 mg/40 mg/40 mg; 160 mg/80 mg/80 mg and 560 mg/320 mg/320 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 27746226

Group type: EXPERIMENTAL
Intervention: LAIV (live attenuated influenza vaccine)
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 1761
Study: 25498067

Group type: EXPERIMENTAL
Intervention: Supervised multidisciplinary rehabilitation program (GH method)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 17
Study: 23210417

Group type: EXPERIMENTAL
Intervention: Test chewing gum containing zinc acetate 0.012% and magnolia bark extract 0.15%
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control chewing gum (sugar-free, without active agents)
Number of subjects: 123
Study: 20110750

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 45
Study: 18378844

Group type: EXPERIMENTAL
Intervention: Dementia care management program (educational and supportive group for caregivers, 6 months duration)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 88
Study: 18402944

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15837660

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia (L group, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA group, n=20)
Number of subjects: 40
Study: 11452703

Group type: EXPERIMENTAL
Intervention: Warfarin 10 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Warfarin 10 mg plus Vitamin K 10 mg
Number of subjects: 11
Study: 9610586

Group type: EXPERIMENTAL
Intervention: Microwave treatment (n = 125)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Sham treatment (n = 44)
Number of subjects: 169
Study: 7528584

Group type: EXPERIMENTAL
Intervention: HHES (hypertonic saline hydroxyethyl starch solution) 4 ml.kg‐1
Number of subjects: 27

Group type: COMPARATOR
Intervention: HES (control group)
Number of subjects: 27
Study: 3228576

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) albuterol 8 mg tablet every 12 h for 8 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Immediate-release (IR) albuterol 4 mg tablet every 6 h for 8 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) albuterol
Number of subjects: 15
Study: 30716933

Group type: EXPERIMENTAL
Intervention: Low-alcohol orange beverage (500 mL/day for 2 weeks)
Number of subjects: 18
Study: 30264896

Group type: EXPERIMENTAL
Intervention: LSVT LOUD (voice), n = 22
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LSVT ARTIC (articulation), n = 20
Number of subjects: 64

Group type: COMPARATOR
Intervention: UNTXPD (untreated), n = 22
Number of subjects: 64
Study: 25784207

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion prior to CVC placement in group A (25 patients)
Number of subjects: 67

Group type: COMPARATOR
Intervention: CVC placement in patients with PLT count above 50×10^9/L (group B, 42 patients)
Number of subjects: 67
Study: 24372522

Group type: EXPERIMENTAL
Intervention: Buddhism-based walking meditation (BWM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Traditional walking exercise (TWE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 45
Study: 22121069

Group type: EXPERIMENTAL
Intervention: Five-minute heart rate variability (HRV)
Number of subjects: 470
Study: 19395686

Group type: EXPERIMENTAL
Intervention: Minimal-contact behavioral treatment (n = 392)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Usual care (n = 393)
Number of subjects: 785
Study: 17627902

Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEB) TACE
Number of subjects: 30
Study: 16241932

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group training (CBGT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Blood glucose awareness training (BGAT)
Number of subjects: 107
Study: 12134181

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine with adrenaline (1:8,00,000)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.5% lignocaine without adrenaline
Number of subjects: 41
Study: 10023791

Group type: EXPERIMENTAL
Intervention: Salmeterol (2 puffs: 42 mcg BID)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Albuterol (2 puffs, 180 mcg QID)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salmeterol (2 puffs)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salmeterol (4 puffs: 84 mcg BID)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salmeterol (4 puffs)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Albuterol (4 puffs, 360 mcg BID)
Number of subjects: 18
Study: 7753965

Group type: EXPERIMENTAL
Intervention: ZK 93,426 (0.04 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2325251

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3mg in 10ml of saline solution with epinephrine 50 micrograms added
Number of subjects: 14

Group type: COMPARATOR
Intervention: Epidural morphine 3mg in 10ml of saline solution without epinephrine
Number of subjects: 14
Study: 34084

Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30912701

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g L−1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 g L−1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: NeuroCart® tests (laboratory tests)
Number of subjects: 24
Study: 28012553

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 0
Study: 25894688

Group type: EXPERIMENTAL
Intervention: Home-based self-management intervention
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: External assessments (outside observations and tape recordings)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Internal evaluation methods (through study nurse forms and notes)
Number of subjects: 101
Study: 23708322

Group type: EXPERIMENTAL
Intervention: Myo-inositol (1.1 g) plus D-chiro-inositol (27.6 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-chiro-inositol (500 mg)
Number of subjects: 0
Study: 21468753

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 559

Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 559
Study: 19767796

Group type: EXPERIMENTAL
Intervention: Increased Training (IT) load
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal Training (NT)
Number of subjects: 18
Study: 17327247

Group type: EXPERIMENTAL
Intervention: Dual chamber enhancements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ventricular‐only enhancements
Number of subjects: 0
Study: 14985687

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid combined with 0.25 mg vitamin B12 (n=9)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10 mg vitamin B6 (n=8)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 50 mg vitamin B6 (n=9)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5 mg vitamin B6 (n=8)
Number of subjects: 42
Study: 11583721

Group type: EXPERIMENTAL
Intervention: Simvastatin 5-10 mg/day for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 32